Bristol Myers Squibb Co is significantly upgrading its computational capabilities by deploying an NVIDIA Corp DGX SuperPOD equipped with DGX Vera Rubin NVL72 systems. The strategic deployment establishes the most robust and energy-efficient single-owned artificial intelligence infrastructure currently operating within the life sciences sector. The expanded Vera Rubin infrastructure will deliver up to ten times greater performance per megawatt than its predecessor, allowing the company to pursue larger and more sophisticated AI workloads without a proportional increase in energy consumption.

The investment builds on nearly three years of collaboration that began when Bristol Myers Squibb first deployed NVIDIA DGX SuperPOD infrastructure. This expansion extends a relationship that matches the growing scope of the company's AI-driven scientific programs across oncology, hematology, cardiovascular, immunology, and neuroscience. The move also builds on the company’s broader AI strategy, including a strategic agreement with Anthropic signed in May to deploy AI across its operations and give more than 30,000 employees access to institutional knowledge.

Strategic Impact on Operations

Bristol Myers Squibb's investment in AI-powered research has already begun to alter how the company discovers and develops medicines. AI agents that automate target identification and validation save scientists weeks of manual work, allowing researchers to focus on hypothesis testing and high-value scientific decisions. Through the company's "Predict First" approach, AI-generated predictions inform experimental design before work begins at the bench. Bristol Myers said AI now supports the design of every small-molecule drug program and most large-molecule development projects.

The enhanced computing capacity will support the development of next-generation foundation models trained on decades of proprietary research data. It also draws on domain-specific capabilities from BioNeMo, NVIDIA's platform for biological AI. The announcement follows another AI-focused partnership unveiled in May with Tempus AI Inc., where the companies agreed to use AI and multimodal real-world data to improve clinical trial design across five initial oncology and neuroscience development programs.

Executive Perspectives

"BMS has made a deliberate bet on AI, and we are beginning to see it pay off in our pipeline and operations," said Greg Meyers, Chief Digital and Technology Officer at Bristol Myers Squibb. "We're committed to translating AI into real outcomes for patients which requires infrastructure built to match that ambition."

"Drug discovery is a sequence of decisions made under uncertainty, and better decisions come from better evidence, faster," said Robert Plenge, Executive Vice President and Chief Research Officer at Bristol Myers Squibb. "This infrastructure lets us learn from every experiment and every clinical readout to sharpen the next hypothesis."

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) for patients with relapsed or refractory multiple myeloma (RRMM). The FDA has granted a Prescription Drug User Fee Act (PDUFA) date of May 13, 2027, for this indication. The acceptance marks progress in the company's targeted protein degradation programs, addressing a persistent disease area.

The filing is supported by positive results from the Phase 3 SUCCESSOR-2 trial. The study demonstrated that MeziKd significantly improved progression-free survival (PFS) compared to the standard of care regimen (Kd). The data showed a median PFS of 18.0 months for MeziKd versus 8.3 months for Kd, representing a 52% reduction in the risk of disease progression or death (HR: 0.48; p<0.0001). The safety profile was consistent with prior studies of mezigdomide and the known profiles of the individual agents.

SUCCESSOR-2 Trial Details

The SUCCESSOR-2 trial is an inferential, seamless Phase 3, multicenter, randomized, open-label study. It evaluated the efficacy and safety of MeziKd versus carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma. The primary endpoint was progression-free survival.

The analysis included 479 patients, with 288 receiving MeziKd and 191 receiving Kd. The median age of patients was 68, with 25.1% aged 75 or older. Patients had received a median of two prior therapies. The study population was heavily pre-treated, with 92.1% of patients triple-class-exposed, 85.8% refractory to an anti-CD38 monoclonal antibody, and 75.8% refractory to lenalidomide.

Cristian Massacesi, MD, executive vice president, chief medical officer and head of development at Bristol Myers Squibb, highlighted the significance of the acceptance. He stated that the company now has two distinct agents under review for this indication and remains committed to leveraging its CELMoD platform to advance treatments for hematologic malignancies and solid tumors.

Mezigdomide is an oral cereblon E3 ligase modulator (CELMoD) optimized to degrade Ikaros and Aiolos target proteins. It is currently being evaluated in the ongoing Phase 3 SUCCESSOR-1 trial as well. The results from the SUCCESSOR-2 trial were recently presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and published in The Lancet.